Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Safety and Feasibility of Next-Generation Dome Helmet (NGDH) for Focused Ultrasound Neuromodulation in Substance Use Disorder (SUD)

2. července 2026 aktualizováno: Dr. Nir Lipsman, Sunnybrook Health Sciences Centre

Assessment of Safety and Feasibility of Focused Ultrasound (FUS) Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Substance Use Disorder (SUD)

The goal of this clinical trial is to evaluate the safety, feasibility, and preliminary clinical benefit of focused ultrasound (FUS) neuromodulation using the FUS Next Generation Dome Helmet (NGDH) in adults with treatment-resistant moderate-to-severe substance use disorder (SUD).

The main questions it aims to answer are:

Can FUS neuromodulation be safely delivered to the nucleus accumbens (NAc) and/or anterior insula (aI)? Does FUS neuromodulation result in reduced substance use severity, as measured by Timeline Followback (TLFB), by 4 weeks post-treatment?

Participants will:

Complete baseline clinical assessments, questionnaires, imaging, and safety assessments.

Undergo two MRI-guided FUS neuromodulation sessions approximately 4 weeks apart.

Attend follow-up visits for safety monitoring, symptom assessments, quality-of-life measures, and additional imaging where applicable.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

A total of 20 participants with treatment-resistant moderate-to-severe substance use disorder (SUD) will be enrolled and treated in this study. Participants will be enrolled from the local practices of the psychiatrists/addiction physicians involved in the study and through outside referrals, including physician referrals or self-referrals. Patient eligibility will be assessed at a screening appointment by the study coordinator and a physician associated with the study. The anticipated enrollment period is approximately two years.

Typ studie

Intervenční

Zápis (Odhadovaný)

20

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Anusha Baskaran, PhD
  • Telefonní číslo: 61650 416-480-6100

Studijní záloha kontaktů

Studijní místa

  • Kanada
    • Ontario
      • Toronto, Ontario, Kanada, M4N 3M5
        • Nábor
        • Sunnybrook Health Sciences Centre
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  1. Must be deemed to have capacity to provide informed consent (determined by the investigator)
  2. Age between 18 to 70 (inclusive)
  3. Diagnosis of SUD (cannabis, alcohol, ketamine, stimulant, opioid or nicotine/tobacco use disorder) in the moderate to severe range according to the DSM-5
  4. Previous ≥2 pharmacotherapy trials for the diagnosed SUD according to guideline-concordant, evidence-based care
  5. On a stable regimen of their psychiatric medications for 30 days before enrolment.

Exclusion Criteria:

  1. Pregnant or intending to be pregnant during the study
  2. Known active seizure disorder, significant head injury with an imaging verified lesion
  3. Medical illness that is deemed to be unstable or may confound the effects of the intervention
  4. Not eligible for 3-Tesla MRI (i.e. MRI-incompatible pacemaker)
  5. Unable to reliably attend the required screening, treatment, and follow up appointments.
  6. Severe claustrophobia, identified by the subject to be a limiting factor preventing MRI.
  7. Scores 18 or below on Montreal Cognitive Assessment (MoCA)
  8. Weighs 250 lbs or more.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Focused Ultrasound Neuromodulation - NAc First
Participants will undergo two focused ultrasound (FUS) neuromodulation sessions spaced four weeks apart. Treatments will target the nucleus accumbens and anterior insula. One of the two sessions may include sham exposure or active control sonication.
Přístroj: Next Generation Dome Helmet (NGDH)
Focused ultrasound (FUS) neuromodulation delivered using the Next Generation Dome Helmet (NGDH) system under MRI guidance. The device delivers low-intensity pulsed ultrasound to targeted brain regions, including the nucleus accumbens and anterior insula, to modulate neural activity. Participants will undergo two treatment sessions spaced four weeks apart. One session may include sham exposure in which the device is positioned identically but no therapeutic ultrasound energy is delivered.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence and Severity of Adverse Events
Časové okno: From baseline (prior to first treatment) through 4 weeks after the second treatment, including assessments on the day of each treatment, 1 day, 1 week, and 2 weeks after each treatment, and at 4 weeks after the second treatment.
Safety will be evaluated by assessing the incidence, severity, and relationship of adverse events associated with FUS neuromodulation.
From baseline (prior to first treatment) through 4 weeks after the second treatment, including assessments on the day of each treatment, 1 day, 1 week, and 2 weeks after each treatment, and at 4 weeks after the second treatment.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Number of Drinking Days Using the Timeline Followback (TLFB)
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
The Timeline Followback (TLFB) is a validated calendar-based self-report method used to assess daily alcohol consumption over a defined period. Participants will report the number of standard drinks consumed each day over the previous 30 days. The total number of days on which alcohol was consumed will be calculated.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Change in Average Number of Drinks per Drinking Day Using TLFB
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Participants' daily alcohol consumption over the previous 30 days will be assessed using the TLFB. The average number of standard drinks per drinking day will be calculated.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Change in Percent Days Abstinent Using TLFB
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Using TLFB data, the percentage of days during the assessment period on which no alcohol was consumed will be calculated.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Change in Number of Heavy Drinking Days Using TLFB
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Heavy drinking days will be defined as ≥5 drinks per day for men and ≥4 drinks per day for women. The number of such days over the assessment period will be calculated using TLFB data.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Subjective Ratings of Mood, Anxiety, Energy, and Optimism Using 1-9 Likert Scales
Časové okno: Baseline, immediately before and after each treatment, 24 hours after each treatment, and 2 and 4 weeks after the second treatment

Participants will complete a brief set of self-reported Likert scales rating their current mood, anxiety, energy level, and optimism for the future. Each item is scored on a 1 to 9 scale, where:

1 = very low/poor 9 = very high/excellent These scales are used to capture rapid, subjective changes in well-being and affective state across the course of treatment.
Baseline, immediately before and after each treatment, 24 hours after each treatment, and 2 and 4 weeks after the second treatment
Change in Depressive Symptoms Using the Hamilton Depression Rating Scale (HAMD-17)
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
The HAMD-17 is a clinician-administered scale with 17 items measuring the severity of depressive symptoms. Total scores range from 0 to 52, with higher scores indicating more severe depression.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Change in anxiety symptoms using the Beck Anxiety Inventory (BAI)
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Anxiety symptoms will be assessed using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire. Each item is scored from 0 to 3, with a total score range of 0 to 63. Higher scores indicate greater anxiety symptom severity. Scores will be compared from baseline to post-treatment follow-up assessments.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
Change in drug use severity using the Drug Use Disorders Identification Test (DUDIT)
Časové okno: Baseline, 3 months after the second treatment, and 6 months after the second treatment
Drug use severity will be assessed using the Drug Use Disorders Identification Test (DUDIT) in participants with drug-related substance use disorder, including stimulant, opioid, and/or ketamine use disorder. The DUDIT is an 11-item instrument used to assess drug-related problems. Items 1-9 are scored from 0 to 4, and items 10-11 are scored as 0, 2, or 4. The total score ranges from 0 to 44, with higher scores indicating greater drug use severity or greater likelihood of drug-related problems. Scores will be compared from baseline to post-treatment follow-up assessments.
Baseline, 3 months after the second treatment, and 6 months after the second treatment
Barratt Impulsiveness Scale (BIS-11)
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
The Barratt Impulsiveness Scale (BIS-11) is a widely utilized 30-item self-report instrument for assessing impulsivity. It is designed for the assessment of impulsivity in both research and clinical settings.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
DSM-5 substance use disorders symptom checklist
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment.
11-item checklist based on behaviors over the past 12 months, classified as mild (2-3 symptoms), moderate (4-5), or severe (6+). Key symptoms include failed attempts to cut down, using more than intended, cravings, neglecting obligations, and continued use despite problems.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment.
The Colorado Symptom Index (CSI)
Časové okno: Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment
14-item, self-report questionnaire designed to measure the frequency of psychiatric symptoms (e.g., depression, anxity, psychosis) over the past month.
Baseline, 2 weeks after the first treatment, and 2 and 4 weeks after the second treatment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Sunnybrook Health Sciences Centre

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. července 2026

Primární dokončení (Odhadovaný)

1. července 2028

Dokončení studie (Odhadovaný)

1. července 2028

Termíny zápisu do studia

První předloženo

8. srpna 2025

První předloženo, které splnilo kritéria kontroly kvality

2. července 2026

První zveřejněno (Aktuální)

6. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

6. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. července 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 6703

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Porucha užívání látek (SUD)

Klinické studie na Next Generation Dome Helmet (NGDH)

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Bahamas

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

3
Předplatit